3a-hydroxy-3,5a,9-trimethyl-4,5,6,7,8,9b-hexahydro-3H-benzo[g][1]benzofuran-2-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3a-hydroxy-3,5a,9-trimethyl-4,5,6,7,8,9b-hexahydro-3H-benzo[g][1]benzofuran-2-one
• 化学式: C₁₅H₂₂O₃
• 分子量: 250.33
• InChiKey: JJTIUYSMVWORIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS TRICYCLIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2009016565A1

  公开（公告）日：2009-02-05

  The present invention provides compounds represented by general formula (1) wherein, R1 R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-α and/or interleukins (IL-1β, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula (1) and pharmaceutical compositions containing them.

  本发明提供了由通式（1）表示的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和X如规范中定义的那样，在所有立体异构体和互变异构体形式以及它们的混合物中的所有比例中，以及其药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的多型体和前药。这些化合物对于治疗包括由促炎细胞因子水平升高引起的炎症性疾病很有用，如肿瘤坏死因子（TNF-α）和/或白细胞介素（IL-1β、IL-6、IL-8）。该发明还涉及制备通式（1）化合物的方法以及含有它们的制药组合物。
• TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
  申请人：Bhedi Dilip Narayanrao

  公开号：US20110009396A1

  公开（公告）日：2011-01-13

  The present invention provides compounds represented by formula 1: wherein, R 1 R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-α and/or interleukins (IL-1β, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula 1 and pharmaceutical compositions containing them.

  本发明提供了由式1所表示的化合物，其中，R1R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和X在规范中定义，包括其所有立体异构体和互变异构体以及在所有比例中的混合物，以及其药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的多晶形和前药。这些化合物可用于治疗炎症性疾病，包括由前炎症细胞因子如肿瘤坏死因子（TNF-α）和/或白细胞介素（IL-1β、IL-6、IL-8）水平升高引起的疾病。本发明还涉及制备式1化合物的方法和含有它们的制药组合物。
• US8981131B2
  申请人：——

  公开号：US8981131B2

  公开（公告）日：2015-03-17